CANNABIS BASED PRODUCTS FOR MEDICINAL USE STAKEHOLDER BRIEFING HOSTED BY HO, MHRA & DHSC

On Thursday 11th October 2018 changes to the Misuse of Drugs Act to allow the prescription of Cannabis-Based Products for Medical Use in Humans have been laid and will become law on 1st November 2018

Details of the changes to be made to the Misuse of Drugs Act (Statutory Instrument (SI))

Last week, Families4Access attended a Stakeholder Briefing hosted at the Home Office. Here we had the opportunity to put some questions to the policy makers and obtain insight on the procedures being developed to enable families to have access to cannabis based medicine.

KEY TAKEAWAYS

No policy restrictions on allowable product types as long as they are produced for human consumption as a medicine and to GMP manufacturing standards, and have been approved by the MHRA.

No policy restrictions on conditions for which cannabis-based products can be prescribed for - Specialists retain authority to prescribe outside of published guidelines if they believe there is a clinical benefit

FULL DETAILS FROM THE HOME OFFICE BRIEFING

Representatives from Patients Groups, Epilepsy Action, Families4Access, Macmillan, MS Society, MS Trust, The Brain Tumour Charity, United Patients Alliance and Young Epilepsy were present along with senior members of the Department of Health and Social Care, Medicines and Healthcare Products Regulatory Authority (MHRA), NHS England, Health Education England and the Home Office.

We have now received the full Slide Pack from the Briefing and have been asked to cascade the information into the Public Domain. So here it is.

BASIA ZIENIEWICZ